Physician profile
Thomas Mueller
NPI 1689684904
$1,563.10
in general payments reported to CMS, 2019-2025
23 companies · $337 in 2025
The $337 reported for 2025 was more than what a typical Family Medicine provider received nationally (typical 2025 total: $153).
Payments by year
General payments by program year, as reported to CMS.
General payments by year: 2019: $113 · 2021: $56.78 · 2022: $131 · 2023: $306 · 2024: $620 · 2025: $337.
What the payments were for
Nature of payment as categorized by the reporting companies: meals, consulting, travel, and so on.
Food and Beverage: $1,246 · Entertainment: $16.93.
View as a table
| Payment type | Amount (2023-2025) |
|---|---|
| Food and Beverage | $1,245.92 |
| Entertainment | $16.93 |
Payment-type detail covers 2023-2025; earlier years are included in totals but not broken out here.
Who reported paying
General payments only, as reported to CMS. Product names cover 2023-2025.
| Company | General payments | Years | Top products |
|---|---|---|---|
| Abbvie INC. | $412.47 | 2021-2025 | |
| Abiomed | $154.90 | 2024-2025 | Impella |
| Glaxosmithkline, LLC. | $136.69 | 2023-2025 | Trelegy Ellipta, Arexvy, Shingrix |
| Astrazeneca Pharmaceuticals Lp | $117.92 | 2022-2025 | Farxiga, Breztri |
| Exact Sciences Corporation | $101.37 | 2023-2025 | Cologuard Collection Kit |
| Regeneron Healthcare Solutions, INC. | $74.58 | 2024-2025 | Dupixent |
| Dexcom, INC. | $68.91 | 2024 | Dexcom G6 Transmitter |
| Roche Diagnostics Corporation | $61.59 | 2019 | |
| Amgen INC. | $58.92 | 2024 | Evenity, Prolia |
| Insmed, INC. | $52.21 | 2024-2025 | Arikayce |
| Genzyme Corporation | $51.45 | 2024 | |
| Merck Sharp & Dohme LLC | $42.82 | 2024 | Vaxneuvance, Gardasil 9, Gardasil |
| Sunovion Pharmaceuticals INC. | $40.07 | 2019 | |
| Otsuka America Pharmaceutical, INC. | $29.82 | 2024 | Rexulti |
| Viatris Specialty LLC | $26.43 | 2025 | Yupelri |
Show all 23 companies
| Company | General payments | Years | Top products |
|---|---|---|---|
| Ethicon US, LLC | $21.03 | 2024 | Stratafix, Ethicon, Dermabond |
| Lilly USA, LLC | $19.63 | 2025 | Jardiance |
| Inogen, INC. | $17.01 | 2025 | |
| Optos, INC. | $16.93 | 2025 | Panoramic Ophthalmoscope, Oct Ophthalmoscope, Nfc-700 |
| Janssen Pharmaceuticals, INC | $16.12 | 2023 | Xarelto |
| Cranial Technologies, INC | $16.04 | 2023 | Doc Band |
| Astellas Pharma US INC | $15.24 | 2024 | Veozah |
| Novo Nordisk INC | $10.95 | 2019 |
Drugs and devices associated with these payments
CMS records which products a payment was associated with, not how the money was allocated. Association is not allocation: one payment can be associated with several products, and a product listing does not mean the payment was made because of that product. Product detail covers 2023-2025.
If you want to bring it up
Most clinicians are glad to talk about this. A respectful way in:
- "I saw Thomas Mueller listed in the CMS Open Payments database. Can you tell me about your work with those companies?"
- "Is there a generic or alternative to this medication, and would it work as well for me?"
- "What made you choose this particular treatment for my situation?"
These are normal questions. A good clinician will welcome them.
Share this page
Keep an eye on this page
Get an email when the next June refresh changes this page. No account needed.
Source: CMS Open Payments, program years 2019-2025, as reported to CMS by drug and device makers (published June 30, 2026). Drug and device detail covers 2023-2025.